Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Definitive radiochemotherapy with 5‑FU/cisplatin with or without cetuximab in unresectable esophageal cancer
2010-023427-18Phase 2Terminated
- Sponsor
- University Hospital Schleswig-Holstein
- Start
- May 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of cetuximab in esophageal cancer (2 arms), sponsored by University Hospital Schleswig-Holstein. Primary endpoint: 2-year overall survival rate. Started May 2011; status: terminated.
02
Drugs
cetuximab
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on 2010-023427-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023427-18.